nach oben

Erschienen in:

01.02.2014

RETRACTED ARTICLE: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients

verfasst von: Giuseppe Derosa, Arrigo F. G. Cicero, Anna Carbone, Fabrizio Querci, Elena Fogari, Angela D’Angelo, Pamela Maffioli

Erschienen in: Inflammation | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

This study aims to evaluate the effects of an angiotensin receptor blocker (ARB)/calcium channel blocker combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation markers. We randomized 276 hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following: body weight, systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1β (MIP-1β). Olmesartan/amlodipine combination better reduced blood pressure, FPI, homeostasis model assessment index, and increased M value and ADN compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased Hs-CRP, MCP-1, and MIP-1β. In this multicenter, randomized, double-blind, clinical study, ARB/calcium antagonist combination resulted to be more effective than single monotherapies in reducing blood pressure, in improving insulin sensitivity, and in reducing inflammation parameters in patients with stage I essential hypertension.

Grundy, S.M., J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr., J.A. Spertus, F. Costa, American Heart Association, and National Heart, Lung, and Blood Institute. 2005. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112(17): 2735–2752.PubMedCrossRef

WRITING GROUP MEMBERS, D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, G. De Simone, T.B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P.M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M.M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V.L. Roger, W. Rosamond, R. Sacco, P. Sorlie, V.L. Roger, T. Thom, S. Wasserthiel-Smoller, N.D. Wong, J. Wylie-Rosett, and American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2010. Heart disease and stroke statistics—2010 update: A report from the American Heart Association. Circulation 121(7): e46–e215.

Gradman, A.H., J.N. Basile, B.L. Carter, G.L. Bakris, and American Society of Hypertension Writing Group. 2010. Combination therapy in hypertension. Journal of the American Society of Hypertension 4(1): 42–50.PubMedCrossRef

Wald, D.S., M. Law, J.K. Morris, J.P. Bestwick, and N.J. Wald. 2009. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. American Journal of Medicine 122(3): 290–300.CrossRefPubMed

de la Sierra, A., and M. Volpe. 2013. Olmesartan-based therapies: An effective way to improve blood pressure control and cardiovascular protection. Journal of Hypertension 31(1): S13–S17.PubMedCrossRef

Lichtenstein, A.H., L.J. Appel, M. Brands, M. Carnethon, S. Daniels, H.A. Franch, B. Franklin, P. Kris-Etherton, W.S. Harris, B. Howard, N. Karanja, M. Lefevre, L. Rudel, F. Sacks, L. Van Horn, M. Winston, and J. Wylie-Rosett. 2006. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 2186–2191.PubMedCrossRef

Epstein, B.J., K. Vogel, and B.F. Palmer. 2007. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67(9): 1309–1327.PubMedCrossRef

Oparil, S., and M. Weber. 2009. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: An emerging strategy in hypertension therapy. Postgraduate Medicine 121(2): 25–39.PubMedCrossRef

Gradman, A.H., J.N. Basile, B.L. Carter, G.L. Bakris, B.J. Materson, H.R. Black, J.L. Izzo Jr., S. Oparil, and M.A. Weber. 2010. Combination therapy in hypertension. Journal of the American Society of Hypertension 4(2): 90–98.PubMedCrossRef

10.

Nesbitt, S.D., A. Shojaee, J.F. Maa, and M.R. Weir. 2013. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). Journal of Human Hypertension 27(7): 445–452.PubMedCrossRef

11.

European Diabetes Policy Group. 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 16: 716–730.CrossRef

12.

Heding, L.G. 1972. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260–266.PubMedCrossRef

13.

Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.PubMedCrossRef

14.

Klose, S., and K. Borner. 1978. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). Journal of Clinical Chemistry and Clinical Biochemistry 15: 121–130.

15.

Wahlefeld, A.W. 1974. Triglycerides determination after enzymatic hydrolysis. In Methods of enzymatic analysis, 2nd ed, ed. H.U. Bermeyer, 18–31. New York: Academic.

16.

Havel, R.J., H.A. Edr, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation 34: 1345–1353.PubMedCentralCrossRefPubMed

17.

Friedewald, W.T., R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499–502.PubMedCrossRef

18.

Yamauchi, T., J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, and T. Kadowaki. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7: 941–946.PubMedCrossRef

19.

Rifai, N., R.P. Tracy, and P.M. Ridker. 1999. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 45(12): 2136–2141.PubMedCrossRef

20.

Hasegawa, M., S. Sato, and K. Takehara. 1999. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clinical and Experimental Immunology 117: 159–165.PubMedPubMedCentralCrossRef

21.

De Fronzo, R.A., J.A. Tobin, and B. Andres. 1979. Glucose clamp technique, a method for quantifying insulin secretion and resistance. American Journal of Physiology 237: 214–223.

22.

Ferrannini, E., G. Buzzigoli, R. Bonadonna, M.A. Giorico, M. Oleggini, L. Graziadei, R. Pedrinelli, L. Brandi, and S. Bevilacqua. 1987. Insulin resistance in essential hypertension. New England Journal of Medicine 317(6): 350–357.CrossRefPubMed

23.

Winer, B.J. 1971. Statistical principles in experimental design, 2nd ed. New York: McGraw-Hill.

24.

Fogari, R., A. Zoppi, A. Mugellini, P. Preti, T. Perrone, P. Maffioli, and G. Derosa. 2012. Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. Expert Opinion on Pharmacotherapy 13(5): 629–636.PubMedCrossRef

25.

Derosa, G., P. Maffioli, S.A. Salvadeo, I. Ferrari, A. Gravina, R. Mereu, I. Palumbo, E. Fogari, A. D’Angelo, and A.F. Cicero. 2010. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertension Research 33(8): 790–795.PubMedCrossRef

26.

Fogari, R., G. Malamani, L. Corradi, A. Mugellini, P. Preti, A. Zoppi, and G. Derosa. 2010. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Advances in Therapy 27(1): 48–55.PubMedCrossRef

27.

Fogari, R., G. Derosa, A. Zoppi, A. Rinaldi, P. Preti, P. Lazzari, and A. Mugellini. 2008. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertension Research 31(1): 43–50.PubMedCrossRef

28.

Fogari, R., G. Derosa, A. Zoppi, P. Lazzari, L. Corradi, P. Preti, and A. Mugellini. 2008. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Internal Medicine 47(5): 361–366.PubMedCrossRef

29.

Fogari, R., A. Zoppi, A. Mugellini, P. Preti, M. Destro, A. Rinaldi, and G. Derosa. 2006. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Advances in Therapy 23(5): 680–695.PubMedCrossRef

30.

Fogari, R., A. Zoppi, A. Mugellini, P. Maffioli, P. Preti, and G. Derosa. 2012. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opinion on Pharmacotherapy 13(8): 1091–1099.PubMedCrossRef

31.

Fogari, R., P. Maffioli, A. Mugellini, A. Zoppi, P. Lazzari, and G. Derosa. 2012. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. European Journal of Gastroenterology and Hepatology 24(2): 164–171.PubMedCrossRef

32.

Fogari, R., A. Zoppi, P. Maffioli, P. Lazzari, A. Mugellini, and G. Derosa. 2011. Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opinion on Pharmacotherapy 12(16): 2441–2448.PubMedCrossRef

33.

Fogari, R., A. Mugellini, M. Destro, L. Corradi, P. Lazzari, A. Zoppi, P. Preti, and G. Derosa. 2012. Losartan and amlodipine on myocardial structure and function: A prospective, randomized, clinical trial. Diabetic Medicine 29(1): 24–31.PubMedCrossRef

34.

Fogari, R., A. Zoppi, A. Mugellini, P. Maffioli, P. Lazzari, C. Monti, and G. Derosa. 2011. Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: A three-way crossover study. Expert Opinion on Pharmacotherapy 12(9): 1351–1358.PubMedCrossRef

35.

Derosa, G., and P. Maffioli. 2011. Drug safety evaluation of amlodipine. Expert Opinion on Drug Safety 10(5): 795–804.PubMedCrossRef

36.

Chrysant, S.G., M. Melino, S. Karki, J. Lee, and R. Heyrman. 2008. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clinical Therapeutics 30(4): 587–604.PubMedCrossRef

37.

Jackson, M.B., and R.S. Ahima. 2006. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clinical Science 110: 143–152.PubMedCrossRef

38.

Berg, A.H., T.P. Combs, and P.E. Scherer. 2002. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism 13: 84–89.PubMedCrossRef

39.

Bouskila, M., U.B. Pajvani, and P.E. Scherer. 2005. Adiponectin: A relevant player in PPARgamma–agonist-mediated improvements in hepatic insulin sensitivity? International Journal of Obesity and Related Metabolic Disorders 29(1): S17–S23.CrossRef

40.

Maeda, N., I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, and Y. Matsuzawa. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 8: 731–737.PubMedCrossRef

41.

Berg, A.H., T.P. Combs, X. Du, M. Brownlee, and P.E. Scherer. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7: 947–953.PubMedCrossRef

42.

Zwacka, T.P., V. Hornbach, and J. Torzewski. 2001. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 103: 1194–1197.CrossRef

43.

Gerszten, R.E., E.A. Garcia-Zepeda, Y.C. Lim, M. Yoshida, H.A. Ding, M.A. Gimbrone Jr., A.D. Luster, F.W. Luscinskas, and A. Rosenzweig. 1999. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398(6729): 718–723.PubMedCrossRef

44.

Charo, I.F., and M.B. Taubman. 2004. Chemokines in the pathogenesis of vascular disease. Circulation Research 95(9): 858–866.PubMedCrossRef

45.

Botti, C., C. Maione, G. Dogliotti, P. Russo, G. Signoriello, A.M. Molinari, M.M. Corsi, V. Sica, and G. Cobellis. 2012. Circulating cytokines present in the serum of peripheral arterial disease patients induce endothelial dysfunction. Journal of Biological Regulators and Homeostatic Agents 26(1): 67–79.PubMed

46.

Tanaka, Y., D.H. Adams, S. Hubscher, H. Hirano, U. Siebenlist, and S. Shaw. 1993. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 361(6407): 79–82.PubMedCrossRef

47.

Schall, T.J., K. Bacon, R.D. Camp, J.W. Kaspari, and D.V. Goeddel. 1993. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. Journal of Experimental Medicine 177(6): 1821–1826.CrossRefPubMed

Titel: RETRACTED ARTICLE: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients
verfasst von: Giuseppe Derosa
Arrigo F. G. Cicero
Anna Carbone
Fabrizio Querci
Elena Fogari
Angela D’Angelo
Pamela Maffioli
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 1/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-013-9724-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Hyperleptinemia: Implications on the Inflammatory State and Vascular Protection in Obese Adolescents Submitted to an Interdisciplinary Therapy

Release-Active Dilutions of Diclofenac Enhance Anti-inflammatory Effect of Diclofenac in Carrageenan-Induced Rat Paw Edema Model

Identification of MicroRNAs Dysregulated in CD14 Gene Silencing RAW264.7 Macrophage Cells

Effects of OX40–OX40L Interaction on the Nuclear Factor of Activated T Cells c1 in ApoE-Deficient Mice

Honokiol Inhibits Tumor Necrosis Factor-α-Stimulated Rat Aortic Smooth Muscle Cell Proliferation via Caspase- and Mitochondrial-Dependent Apoptosis